Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 674063, 12 pages
http://dx.doi.org/10.1155/2014/674063
Review Article

6-[18F]Fluoro-L-DOPA: A Well-Established Neurotracer with Expanding Application Spectrum and Strongly Improved Radiosyntheses

1Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
2Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany

Received 26 February 2014; Revised 17 April 2014; Accepted 18 April 2014; Published 28 May 2014

Academic Editor: Olaf Prante

Copyright © 2014 M. Pretze et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. D. Howes, A. J. Montgomery, M.-C. Asselin, R. M. Murray, P. M. Grasby, and P. K. Mcguire, “Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis,” British Journal of Psychiatry, vol. 191, no. 51, supplement, pp. S13–S18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Bose, F. E. Turkheimer, O. D. Howes et al., “Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging,” Schizophrenia Research, vol. 106, no. 2-3, pp. 148–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Brooks, “PET studies on the function of dopamine in health and Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 22–35, 2003. View at Google Scholar · View at Scopus
  4. D. J. Brooks, K. A. Frey, K. L. Marek et al., “Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease,” Experimental Neurology, vol. 184, no. 1, pp. S68–S79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Cumming, P. Deep, O. Rousset, A. Evans, and A. Gjedde, “On the rate of decarboxylation of Dopa to Dopamine in living mammalian brain,” Annals of the New York Academy of Sciences, vol. 835, pp. 274–308, 1997. View at Google Scholar
  6. T. Nakamura, V. Dhawan, T. Chaly et al., “Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease,” Annals of Neurology, vol. 50, no. 2, pp. 181–187, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Tedroff, R. Torstenson, P. Hartvig et al., “Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity,” Synapse, vol. 28, pp. 280–287, 1998. View at Google Scholar
  8. R. Torstenson, P. Hartvig, B. Långström, S. Bastami, G. Antoni, and J. Tedroff, “Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone,” Neuropharmacology, vol. 37, no. 8, pp. 989–995, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. W. D. Heiss, K. Wienhard, R. Wagner et al., “F-Dopa as an amino acid tracer to detect brain tumors,” Journal of Nuclear Medicine, vol. 37, pp. 1180–1182, 1996. View at Google Scholar
  10. W. Chen, D. H. S. Silverman, S. Delaloye et al., “18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy,” Journal of Nuclear Medicine, vol. 47, no. 6, pp. 904–911, 2006. View at Google Scholar · View at Scopus
  11. S. Oka, H. Okudaira, M. Ono et al., “Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[Methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose,” Molecular Imaging and Biology, vol. 16, no. 3, pp. 322–329, 2013. View at Publisher · View at Google Scholar
  12. Y. Okochi, T. Nihashi, M. Fujii et al., “Clinical use of 11C-methionine and 18F-FDG-PET for germinoma in central nervous system,” Annals of Nuclear Medicine, vol. 28, no. 2, pp. 94–102, 2013. View at Google Scholar
  13. S. Takenaka, Y. Asano, J. Shinoda et al., “Comparison of 11C-methionine, 11C-chlorine, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis,” Neurologia Medico-Chirurgica, vol. 54, no. 4, pp. 280–289, 2014. View at Publisher · View at Google Scholar
  14. W. Chen, T. Cloughesy, N. Kamdar et al., “Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG,” Journal of Nuclear Medicine, vol. 46, no. 6, pp. 945–952, 2005. View at Google Scholar · View at Scopus
  15. L. B. Been, A. J. H. Suurmeijer, D. C. P. Cobben, P. L. Jager, H. J. Hoekstra, and P. H. Elsinga, “[18F]FLT-PET in oncology: current status and opportunities,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 12, pp. 1659–1672, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Galldiks, G. Stoffels, M. I. Ruge et al., “Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma,” Journal of Nuclear Medicine, vol. 54, no. 12, pp. 2046–2054, 2013. View at Google Scholar
  17. M. D. Piroth, J. Prasath, A. Willuweit et al., “Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas,” Nuclear Medicine and Biology, vol. 40, pp. 795–800, 2013. View at Google Scholar
  18. K. K. Sai, C. Huang, L. Yuan et al., “18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas,” Journal of Nuclear Medicine, vol. 54, no. 7, pp. 1120–1126, 2013. View at Google Scholar
  19. K. Zhang, K. J. Langen, I. Neuner et al., “Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-18F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas,” Nuclear Medicine Communications, vol. 35, no. 3, pp. 245–251, 2014. View at Google Scholar
  20. J. P. Seibyl, W. Chen, and D. H. S. Silverman, “3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors,” Seminars in Nuclear Medicine, vol. 37, no. 6, pp. 440–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Isselbacher, “Sugar and amino acid transport by cells in culture: differences between normal and malignant cells,” The New England Journal of Medicine, vol. 286, no. 17, pp. 929–933, 1972. View at Google Scholar · View at Scopus
  22. H. Busch, J. R. Davis, G. R. Honig, D. C. Anderson, P. V. Nair, and W. L. Nyhan, “The uptake of a variety of amino acids into nuclear proteins of tumors,” Cancer Research, vol. 19, pp. 1030–1039, 1959. View at Google Scholar · View at Scopus
  23. O. C. Neels, K. P. Koopmans, P. L. Jager et al., “Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells,” Cancer Research, vol. 68, no. 17, pp. 7183–7190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Minn, S. Kauhanen, M. Seppänen, and P. Nuutila, “18F-FDOPA: a multiple-target molecule,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 1915–1918, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans, and K. Y. Gulenchyn, “6-L-18F-fluorodihydroxyphenylalanine pet in neuroendocrine tumors: basic aspects and emerging clinical applications,” Journal of Nuclear Medicine, vol. 49, no. 4, pp. 573–586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Balogova, J.-N. Talbot, V. Nataf et al., “18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 6, pp. 943–966, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Chondrogiannis, G. Grassetto, M. C. Marzola et al., “18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours,” Nuclear Medicine Communications, vol. 33, no. 2, pp. 179–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Martiniova, S. Cleary, E. W. Lai et al., “Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma,” Nuclear Medicine and Biology, vol. 39, no. 2, pp. 215–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. H. C. Rischke, M. R. Benz, D. Wild et al., “Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L- phenylalanin PET,” Journal of Nuclear Medicine, vol. 53, no. 9, pp. 1352–1358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Tuomela, S. Forsback, L. Haavisto et al., “Enzyme inhibition of dopamine metabolism alters 6-[18F]FDOPA uptake in orthotopic pancreatic adenocarcinoma,” EJNMMI Research, vol. 3, no. 1, article 18, pp. 1–10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Jadvar, “Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers,” Seminars in Nuclear Medicine, vol. 42, no. 4, pp. 247–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. K. P. Koopmans, O. C. Neels, I. P. Kema et al., “Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1489–1495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. W. H. Oldendorf, “Stereospecificity of blood-brain barrier permeability to amino acids,” The American Journal of Physiology, vol. 224, no. 4, pp. 967–969, 1973. View at Google Scholar · View at Scopus
  34. G. Firnau, C. Nahmias, and S. Garnett, “The preparation of [18F]5-fluoro-DOPA with reactor-produced fluorine-18,” The International Journal of Applied Radiation and Isotopes, vol. 24, no. 3, pp. 182–184, 1973. View at Google Scholar · View at Scopus
  35. G. Firnau, S. Sood, R. Pantel, and S. Garnett, “Phenol ionization in dopa determines the site of methylation by catechol-O-methyltransferase,” Molecular Pharmacology, vol. 19, no. 1, pp. 130–133, 1981. View at Google Scholar · View at Scopus
  36. G. Firnau, R. Chirakal, and E. S. Garnett, “Aromatic radiofluorination with [18F]fluorine gas: 6-[18F]fluoro-L-dopa,” Journal of Nuclear Medicine, vol. 25, no. 11, pp. 1228–1233, 1984. View at Google Scholar · View at Scopus
  37. R. J. Nickles, M. E. Daube, and T. J. Ruth, “An 18O2 target for the production of [18F]F2,” International Journal of Applied Radiation and Isotopes, vol. 35, no. 2, pp. 117–122, 1984. View at Publisher · View at Google Scholar · View at Scopus
  38. A. D. Roberts, T. R. Oakes, and R. J. Nickles, “Development of an improved target for [18F]F2 production,” Applied Radiation and Isotopes, vol. 46, no. 2, pp. 87–91, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Hess, S. Sichler, A. Kluge, and H. H. Coenen, “Synthesis of 2-[18F]fluoro-L-tyrosine via regiospecific fluoro-de-stannylation,” Applied Radiation and Isotopes, vol. 57, no. 2, pp. 185–191, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Hatano, K. Ishiwata, and T. Yanagisawa, “Co production of 2, 6-[18F]difluoroDOPA during electrophilic synthesis of 6-[18F]fluoro-L-DOPA,” Nuclear Medicine and Biology, vol. 23, pp. 101–103, 1996. View at Google Scholar
  41. H. H. Coenen, K. Franken, P. Kling, and G. Stöcklin, “Direct electrophilic radiofluorination of phenylalanine, tyrosine and dopa,” Applied Radiation and Isotopes, vol. 39, no. 12, pp. 1243–1250, 1988. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Diksic and S. Farrokhzad, “New synthesis of fluorine-18-labeled 6-fluoro-L-dopa by cleaving the carbon-silicon bond with fluorine,” Journal of Nuclear Medicine, vol. 26, no. 11, pp. 1314–1318, 1985. View at Google Scholar · View at Scopus
  43. M. J. Adam and S. Jivan, “Synthesis and purification of L-6-[18F]fluorodopa,” Applied Radiation and Isotopes, vol. 39, no. 12, pp. 1203–1206, 1988. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Luxen, M. Perlmutter, G. T. Bida et al., “Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET,” Applied Radiation and Isotopes, vol. 41, no. 3, pp. 275–281, 1990. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Bishop, N. Satyamurthy, G. Bida, and J. R. Barrio, “Chemical reactivity of the 18F electrophilic reagents from the 18O(p, n)18F gas target systems,” Nuclear Medicine and Biology, vol. 23, no. 5, pp. 559–565, 1996. View at Google Scholar
  46. T. Chaly, D. Bandyopadhyay, R. Matacchieri et al., “A disposable synthetic unit for the preparation of 3-O-methyl-6-[18F]fluorodopa using a regioselective fluorodemercuration reaction,” Applied Radiation and Isotopes, vol. 45, no. 1, pp. 25–30, 1994. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Namavari, A. Bishop, N. Satyamurthy, G. Bida, and J. R. Barrio, “Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]fluoro-L-dopa,” Applied Radiation and Isotopes, vol. 43, no. 8, pp. 989–996, 1992. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Dollé, S. Demphel, F. Hinnen, D. Fournier, F. Vaufrey, and C. Crouzel, “6-[18F]fluoro-L-DOPA by radiofluorodestannylation: a short and simple synthesis of a new labelling precursor,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 41, no. 2, pp. 105–114, 1998. View at Google Scholar
  49. F. Füchtner, P. Angelberger, H. Kvaternik, F. Hammerschmidt, B. P. Simovc, and J. Steinbach, “Aspects of 6-[18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity,” Nuclear Medicine and Biology, vol. 29, no. 4, pp. 477–481, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Füchtner and J. Steinbach, “Efficient synthesis of the 18F-labelled 3-O-methyl-6-[18F]fluoro-L-DOPA,” Applied Radiation and Isotopes, vol. 58, no. 5, pp. 575–578, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. C. W. Chang, H. E. Wang, H. M. Lin, C. S. Chtsai, J. B. Chen, and R.-S. Liu, “Robotic synthesis of 6-[18F]fluoro-L-dopa,” Nuclear Medicine Communications, vol. 21, no. 9, pp. 799–802, 2000. View at Google Scholar · View at Scopus
  52. M. J. Adam, J. Lu, and S. Jivan, “Stereoselective synthesis of 3-O-methyl-6-[18F]fluorodopa via fluorodestannylation,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 34, no. 6, pp. 565–570, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. E. F. J. de Vries, G. Luurtsema, M. Brüssermann, P. H. Elsinga, and W. Vaalburg, “Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-L-DOPA,” Applied Radiation and Isotopes, vol. 51, no. 4, pp. 389–394, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Luxen, M. Guillaume, W. P. Melega, V. W. Pike, O. Solin, and R. Wagner, “Production of 6-[18F]fluoro-L-DOPA and its metabolism in vivo: a critical review,” Nuclear Medicine and Biology, vol. 19, no. 2, pp. 149–158, 1992. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Hess, G. Blessing, H. H. Coenen, and S. M. Qaim, “Improved target system for production of high purity [18F]fluorine via the 18O(p,n)18F reaction,” Applied Radiation and Isotopes, vol. 52, no. 6, pp. 1431–1440, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Füchtner, S. Preusche, P. Mäding, J. Zessin, and J. Steinbach, “Factors affecting the specific activity of [18F]fluoride from a [18O]water target,” Nuklearmedizin, vol. 47, no. 3, pp. 116–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. K. P. Koopmans, A. H. Brouwers, M. N. De Hooge et al., “Carcinoid crisis after injection of 6-18F- fluorodihydroxyphenylalanine in a patient with metastatic carcinoid,” Journal of Nuclear Medicine, vol. 46, no. 7, pp. 1240–1243, 2005. View at Google Scholar · View at Scopus
  58. T. Tierling, K. Hamacher, and H. H. Coenen, “A new nucleophilic asymmetric synthesis of 6-[18F]fluoro-dopa,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 44, supplement, pp. S146–S147, 2001. View at Google Scholar
  59. F. M. Wagner, J. Ermert, and H. H. Coenen, “Three-step, “one-pot” radiosynthesis of 6-fluoro-3,4-dihydroxy-l-phenylalanine by isotopic exchange,” Journal of Nuclear Medicine, vol. 50, no. 10, pp. 1724–1729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. F. M. Wagner, Zur Synthese radiofluorierter aromatischer Aminosäuren mittels Isotopenaustausch am Beispiel von 6-[18F]Fluor-L-DOPA, " [Ph.D. thesis], Forschungszentrum Jülich, Universität zu Köln, 2007.
  61. R. Martin, D. Baumgart, S. Hübner et al., “Automated nucleophilic one-pot synthesis of 18F-L-DOPA with high specific activity using the GE TRACERlab MXFDG,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 56, supplement S126, 2013. View at Google Scholar
  62. A. Al-Labadi, K.-P. Zeller, and H.-J. Machulla, “Synthesis of 6-[18F]fluoroveratraldehyde by nucleophilic halogen exchange at electron-rich precursors,” Journal of Radioanalytical and Nuclear Chemistry, vol. 270, no. 2, pp. 313–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. Y.-S. Ding, C.-Y. Shiue, J. S. Fowler, A. P. Wolf, and A. Plenevaux, “No-carrier-added (NCA) aryl [18F]fluorides via the nucleophilic aromatic substitution of electron-rich aromatic rings,” Journal of Fluorine Chemistry, vol. 48, no. 2, pp. 189–206, 1990. View at Google Scholar · View at Scopus
  64. C. Lemaire, M. Guillaume, R. Cantineau, and L. Christiaens, “No-carrier-added regioselective preparation of 6-[18F]fluoro-L-dopa,” Journal of Nuclear Medicine, vol. 31, no. 7, pp. 1247–1251, 1990. View at Google Scholar · View at Scopus
  65. C. Lemaire, M. Guillaume, R. Cantineau, A. Plenevaux, and L. Christiaens, “An approach to the asymmetric synthesis of L-6-[18F]fluorodopa via NCA nucleophilic fluorination,” Applied Radiation and Isotopes, vol. 42, no. 7, pp. 629–635, 1991. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Lemaire, P. Damhaut, A. Plenevaux, and D. Comar, “Enantioselective synthesis of 6-[fluorine-18]-fluoro-L-dopa from no-carrier-added fluorine-18-fluoride,” Journal of Nuclear Medicine, vol. 35, no. 12, pp. 1996–2002, 1994. View at Google Scholar · View at Scopus
  67. C. Lemaire, A. Plenevaux, R. Cantineau, L. Christiaens, M. Guillaume, and D. Comar, “Nucleophilic enantioselective synthesis of 6-[18F]fluoro-L-dopa via two chiral auxiliaries,” Applied Radiation and Isotopes, vol. 44, no. 4, pp. 737–744, 1993. View at Google Scholar · View at Scopus
  68. G. N. Reddy, M. Haeberli, H.-F. Beer, and A. P. Schubiger, “An improved synthesis of no-carrier-added (NCA) 6-[18F]fluoro-L-DOPA and its remote routine production for PET investigations of dopaminergic systems,” Applied Radiation and Isotopes, vol. 44, no. 4, pp. 645–649, 1993. View at Google Scholar · View at Scopus
  69. A. Horti, D. E. Redmond Jr., and R. Soufer, “No-carrier-added (NCA) synthesis of 6-[18F]fluoro-L-DOPA using 3,5,6,7,8,8a-hexahydro-7,7,8a-trimethyl-[6S-(6α, 8α, 8αβ)]-6,8-methano-2H-1,4-benzoxazin-2-one,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 36, no. 5, pp. 409–423, 1995. View at Google Scholar · View at Scopus
  70. A. Najafi, “Measures and pitfalls for successful preparation of “no carrier added” asymmetric 6-[18F]fluor-L-dopa from 18F-fluoride ion,” Nuclear Medicine and Biology, vol. 22, no. 3, pp. 395–397, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. E. J. Corey, F. Xu, and M. C. Noe, “A rational approach to catalytic enantioselective enolate alkylation using a structurally rigidified and defined chiral quaternary ammonium salt under phase transfer conditions,” Journal of the American Chemical Society, vol. 119, no. 50, pp. 12414–12415, 1997. View at Google Scholar
  72. C. Lemaire, S. Guillouet, A. Plenevaux, C. Brihaye, J. Aerts, and A. Luxen, “The synthesis of 6-[18F]fluoro-L-dopa by chiral catalytic phase-transfer alkylation,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 42, supplement 1, pp. S113–S115, 1999. View at Google Scholar · View at Scopus
  73. S. Guillouet, C. Lemaire, G. Bonmarchand, L. Zimmer, and D. le Bars, “Large scale production of 6-[18F]fluoro-L-DOPA in a semi-automated system,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 44, supplement, pp. S868–S870, 2001. View at Google Scholar
  74. L. Zhang, G. Tang, D. Yin, X. Tang, and Y. Wang, “Enantioselective synthesis of no-carrier-added (NCA) 6-[18F]fluoro-L-DOPA,” Applied Radiation and Isotopes, vol. 57, no. 2, pp. 145–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Yin, L. Zhang, G. Tang, X. Tang, and Y. Wang, “Enantioselective synthesis of no-carrier added (NCA) 6-[18F]Fluoro-L-Dopa,” Journal of Radioanalytical and Nuclear Chemistry, vol. 257, no. 1, pp. 179–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. “Fluorodopa (18F) (prepared by electrophilic substitution) injection,” European Pharmacopoeia, vol. 6, pp. 990–992, 2008.
  77. S. Kaneko, K. Ishiwata, K. Hatano, H. Omura, K. Ito, and M. Senda, “Enzymatic synthesis of no-carrier-added 6-[18F]fluoro-L-dopa with β- tyrosinase,” Applied Radiation and Isotopes, vol. 50, no. 6, pp. 1025–1032, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Lemaire, S. Gillet, S. Guillouet, A. Plenevaux, J. Aerts, and A. Luxen, “Highly enantioselective synthesis of no-carrier-added 6-[18F]fluoro-L-dopa by chiral phase-transfer alkylation,” European Journal of Organic Chemistry, no. 13, pp. 2899–2904, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Lemaire, L. Libert, A. Plenevaux, J. Aerts, X. Franci, and A. Luxen, “Fast and reliable method for the preparation of ortho- and para-[18F]fluorobenzyl halide derivatives: key intermediates for the preparation of no-carrier-added PET aromatic radiopharmaceuticals,” Journal of Fluorine Chemistry, vol. 138, pp. 48–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. R. N. Krasikova, V. V. Zaitsev, S. M. Ametamey et al., “Catalytic enantioselective synthesis of 18F-fluorinated α-amino acids under phase-transfer conditions using (S)-NOBIN,” Nuclear Medicine and Biology, vol. 31, no. 5, pp. 597–603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. N. Belokon, K. A. Kochetkov, T. D. Churkina et al., “Highly efficient catalytic synthesis of alpha-amino acids under phase-transfer conditions with a novel catalyst/substrate pair,” Angewandte Chemie: International Edition, vol. 40, pp. 1948–1951, 2001. View at Google Scholar
  82. M. Smrčina, J. Poláková, Š. Vyskočil, and P. Kočovský, “Synthesis of enantiomerically pure binaphthyl derivatives. Mechanism of the enantioselective, oxidative coupling of naphthols and designing a catalytic cycle,” Journal of Organic Chemistry, vol. 58, no. 17, pp. 4534–4538, 1993. View at Google Scholar · View at Scopus
  83. B. Shen, W. Ehrlichmann, M. Uebele, H.-J. Machulla, and G. Reischl, “Automated synthesis of n.c.a. [18F]FDOPA via nucleophilic aromatic substitution with [18F]fluoride,” Applied Radiation and Isotopes, vol. 67, no. 9, pp. 1650–1653, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Shen, D. Löffler, G. Reischl, H.-J. Machulla, and K.-P. Zeller, “Nucleophilic [18F]Fluorination and subsequent decarbonylation of methoxy-substituted nitro- and halogen-benzenes activated by one or two formyl groups,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 53, no. 3, pp. 113–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Shen, D. Löffler, K.-P. Zeller, M. Übele, G. Reischl, and H.-J. Machulla, “Effect of aldehyde and methoxy substituents on nucleophilic aromatic substitution by [18F]fluoride,” Journal of Fluorine Chemistry, vol. 128, no. 12, pp. 1461–1468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. L. C. Libert, X. Franci, A. R. Plenevaux et al., “Production at the Curie level of no-carrier-added 6-18F-fluoro-L-dopa,” Journal of Nuclear Medicine, vol. 54, no. 7, pp. 1154–1161, 2013. View at Google Scholar
  87. S.-S. Jew and H.-G. Park, “Cinchona-based phase-transfer catalysts for asymmetric synthesis,” Chemical Communications, no. 46, pp. 7090–7103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Forsback, O. Eskola, M. Haaparanta, J. Bergman, and O. Solin, “Electrophilic synthesis of 6-[18F]fluoro-L-DOPA using post-target produced [18F]F2,” Radiochimica Acta, vol. 96, no. 12, pp. 845–848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Forsback, O. Eskola, J. Bergman, M. Haaparanta, and O. Solin, “Alternative solvents for electrophilic synthesis of 6-[18F] fluoro-L-DOPA,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 52, no. 7, pp. 286–288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. E. Lee, J. M. Hooker, and T. Ritter, “Nickel-mediated oxidative fluorination for PET with aqueous [18F] fluoride,” Journal of the American Chemical Society, vol. 134, no. 42, pp. 17456–17458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. I. S. R. Stenhagen, A. K. Kirjavainen, S. J. Forsback et al., “Fluorination of an arylboronic ester using [18F]selectfluor bis(triflate): application to 6-[18F]fluoro-l-DOPA,” Chemical Communications, vol. 49, no. 14, pp. 1386–1388, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Chirakal, G. Firnau, and E. S. Garnett, “High yield synthesis of 6-[18F]fluoro-L-dopa,” Journal of Nuclear Medicine, vol. 27, no. 3, pp. 417–421, 1986. View at Google Scholar · View at Scopus
  93. K. Ishiwata, S. Ishii, M. Senda, Y. Tsuchiya, and K. Tomimoto, “Electrophilic synthesis of 6-[18F]fluoro-L-DOPA: use of 4-O-pivaloyl-L-DOPA as a suitable precursor for routine production,” Applied Radiation and Isotopes, vol. 44, no. 4, pp. 755–759, 1993. View at Google Scholar · View at Scopus
  94. T. Chaly, J. R. Dahl, R. Matacchieri et al., “Synthesis of 6-[18F]fluorodopamine with a synthetic unit made up of primarily sterile disposable components and operated by a master slave manipulator,” Applied Radiation and Isotopes, vol. 44, no. 5, pp. 869–873, 1993. View at Google Scholar · View at Scopus
  95. F. Füchtner, J. Zessin, P. Mäding, and F. Wüst, “Aspects of 6-[18F]fluoro-L-DOPA preparation,” Nuklearmedizin, vol. 47, pp. 62–64, 2008. View at Google Scholar